129 related articles for article (PubMed ID: 18322448)
1. Influence of CYP3A4, CYP3A5, and ABCB1 genotype and expression on budesonide pharmacokinetics: a possible role of intestinal CYP3A4 expression.
Ufer M; Dilger K; Leschhorn L; Daufresne L; Mosyagin I; Rosenstiel P; Haesler R; Kuehbacher T; Nikolaus S; Schreiber S; Cascorbi I
Clin Pharmacol Ther; 2008 Jul; 84(1):43-6. PubMed ID: 18322448
[TBL] [Abstract][Full Text] [Related]
2. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms in CYP3A5, CYP3A4, and ABCB1 are not associated with cyclosporine pharmacokinetics nor with cyclosporine clinical end points after renal transplantation.
Bouamar R; Hesselink DA; van Schaik RH; Weimar W; Macphee IA; de Fijter JW; van Gelder T
Ther Drug Monit; 2011 Apr; 33(2):178-84. PubMed ID: 21383650
[TBL] [Abstract][Full Text] [Related]
4. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea.
Jun KR; Lee W; Jang MS; Chun S; Song GW; Park KT; Lee SG; Han DJ; Kang C; Cho DY; Kim JQ; Min WK
Transplantation; 2009 Apr; 87(8):1225-31. PubMed ID: 19384171
[TBL] [Abstract][Full Text] [Related]
5. CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients.
Crettol S; Venetz JP; Fontana M; Aubert JD; Pascual M; Eap CB
Ther Drug Monit; 2008 Dec; 30(6):689-99. PubMed ID: 18978522
[TBL] [Abstract][Full Text] [Related]
6. CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III).
Yoon SH; Cho JH; Kwon O; Choi JY; Park SH; Kim YL; Yoon YR; Won DI; Kim CD
Transplantation; 2013 Mar; 95(6):828-34. PubMed ID: 23364483
[TBL] [Abstract][Full Text] [Related]
7. Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms.
Tsai SM; Lin CY; Wu SH; Hou LA; Ma H; Tsai LY; Hou MF
Clin Chim Acta; 2009 Jun; 404(2):160-5. PubMed ID: 19332043
[TBL] [Abstract][Full Text] [Related]
8. Effect of CYP3A4*1G, CYP3A5*3, POR*28, and ABCB1 C3435T on the pharmacokinetics of nifedipine in healthy Chinese volunteers.
Wang XF; Yan L; Cao HM; Wei LM; Yang WH; Zhang SJ; Zhang LR
Int J Clin Pharmacol Ther; 2015 Sep; 53(9):737-45. PubMed ID: 26104034
[TBL] [Abstract][Full Text] [Related]
9. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients.
Shi Y; Li Y; Tang J; Zhang J; Zou Y; Cai B; Wang L
Gene; 2013 Jan; 512(2):226-31. PubMed ID: 23107770
[TBL] [Abstract][Full Text] [Related]
10. Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity.
Guilhaumou R; Solas C; Bourgarel-Rey V; Quaranta S; Rome A; Simon N; Lacarelle B; Andre N
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1633-8. PubMed ID: 21968951
[TBL] [Abstract][Full Text] [Related]
11. Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers.
Belmonte C; Ochoa D; Román M; Saiz-Rodríguez M; Wojnicz A; Gómez-Sánchez CI; Martín-Vílchez S; Abad-Santos F
Basic Clin Pharmacol Toxicol; 2018 Jun; 122(6):596-605. PubMed ID: 29325225
[TBL] [Abstract][Full Text] [Related]
12. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients.
Kuypers DR; de Jonge H; Naesens M; Lerut E; Verbeke K; Vanrenterghem Y
Clin Pharmacol Ther; 2007 Dec; 82(6):711-25. PubMed ID: 17495880
[TBL] [Abstract][Full Text] [Related]
13. Expression of CYP3A isoforms and P-glycoprotein in human stomach, jejunum and ileum.
Canaparo R; Finnström N; Serpe L; Nordmark A; Muntoni E; Eandi M; Rane A; Zara GP
Clin Exp Pharmacol Physiol; 2007 Nov; 34(11):1138-44. PubMed ID: 17880367
[TBL] [Abstract][Full Text] [Related]
14. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens.
von Richter O; Burk O; Fromm MF; Thon KP; Eichelbaum M; Kivistö KT
Clin Pharmacol Ther; 2004 Mar; 75(3):172-83. PubMed ID: 15001968
[TBL] [Abstract][Full Text] [Related]
15. Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment?
Magliulo L; Dahl ML; Lombardi G; Fallarini S; Villa LM; Biolcati A; Scordo MG
Eur J Clin Pharmacol; 2011 Jan; 67(1):47-54. PubMed ID: 20931330
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression.
Pinto AG; Wang YH; Chalasani N; Skaar T; Kolwankar D; Gorski JC; Liangpunsakul S; Hamman MA; Arefayene M; Hall SD
Clin Pharmacol Ther; 2005 Mar; 77(3):178-88. PubMed ID: 15735612
[TBL] [Abstract][Full Text] [Related]
17. Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation.
Gervasini G; Garcia M; Macias RM; Cubero JJ; Caravaca F; Benitez J
Transpl Int; 2012 Apr; 25(4):471-80. PubMed ID: 22369694
[TBL] [Abstract][Full Text] [Related]
18. Expression of cytochromes P450 3A and P-glycoprotein in human large intestine in paired tumour and normal samples.
Canaparo R; Nordmark A; Finnström N; Lundgren S; Seidegård J; Jeppsson B; Edwards RJ; Boobis AR; Rane A
Basic Clin Pharmacol Toxicol; 2007 Apr; 100(4):240-8. PubMed ID: 17371528
[TBL] [Abstract][Full Text] [Related]
19. Genetic variations in ABCB1 and CYP3A5 as well as sex influence quinine disposition among Ugandans.
Mukonzo JK; Waako P; Ogwal-Okeng J; Gustafsson LL; Aklillu E
Ther Drug Monit; 2010 Jun; 32(3):346-52. PubMed ID: 20357698
[TBL] [Abstract][Full Text] [Related]
20. Effect of CYP3A5, CYP3A4, and ABCB1 genotypes as determinants of tacrolimus dose and clinical outcomes after heart transplantation.
Díaz-Molina B; Tavira B; Lambert JL; Bernardo MJ; Alvarez V; Coto E
Transplant Proc; 2012 Nov; 44(9):2635-8. PubMed ID: 23146479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
